Online citations, reference lists, and bibliographies.
← Back to Search

Statins And Cardiovascular Diseases: The Multiple Effects Of Lipid-lowering Therapy By Statins.

U. Rauch, J. Osende, J. Chesebro, V. Fuster, D. Vorchheimer, K. Harris, P. Harris, D. Sandler, J. Fallon, S. Jayaraman, J. Badimon
Published 2000 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Cholesterol lowering involving different therapies improves the clinical outcome of patients. To define the underlying pathomechanism, we studied whether treatment with statins was associated with changes in blood thrombogenicity, endothelial dysfunction and soluble adhesion molecule levels. Fifty hypercholesterolemic patients were treated with pravastatin (40 mg/day, n=24) or simvastatin (20 mg/day, n=26). Lipid profile and blood thrombogenicity were assessed in all patients before and after 3 months of cholesterol reducing therapy. Blood thrombogenicity was assessed as thrombus formation, perfusing non-anticoagulated blood directly from the patients' vein through the Badimon perfusion chamber (shear rate 1690/s). Endothelial-dependent vasomotor response was tested by laser-Doppler flowmeter. Soluble adhesion molecule level were measured by ELISA. Total and LDL cholesterol were reduced in the two treatment groups by statin therapy. Statin therapy was associated with a significant reduction in blood thrombogenicity and endothelium-dependent vasoresponse. No differences were observed between simvastatin or pravastatin treatment. Lipid lowering by statins had no effect on plasma levels of fibrinogen, sL-selectin, sP-selectin and sICAM-1 antigen. Cholesterol lowering by both statins reduced the increased blood reactivity and endothelial dysfunction present under hypercholesterolemia. The multiple effects of lipid lowering therapy by statins may explain the benefits observed in recent epidemiological trials.
This paper references
Characterization of a tubular flow chamber for studying platelet interaction with biologic and prosthetic materials: deposition of indium 111-labeled platelets on collagen, subendothelium, and expanded polytetrafluoroethylene.
L. Badimón (1987)
10.1161/01.CIR.97.10.946
Cholesterol reduction yields clinical benefit: impact of statin trials.
A. L. Gould (1998)
10.1161/01.ATV.18.11.1671
HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages.
S. Bellosta (1998)
10.1136/hrt.80.6.543
Cholesterol lowering and coronary artery disease: mechanisms of risk reduction
R. Archbold (1998)
10.1056/NEJM199502233320802
The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion.
T. Anderson (1995)
10.1001/JAMA.279.20.1643
Antiatherothrombotic properties of statins: implications for cardiovascular event reduction.
R. Rosenson (1998)
10.1161/01.ATV.18.8.1342
Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab.
G. Dangas (1998)
10.1016/S0735-1097(99)00018-2
Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile.
G. Dangas (1999)
10.1161/01.CIR.92.3.657
Coronary plaque disruption.
E. Falk (1995)
10.1038/254056A0
In vivo evaluation of microcirculation by coherent light scattering
M. Stern (1975)
Coronary atherosclerosis. A multifactorial disease.
J. Badimon (1993)
10.1161/01.CIR.91.8.2274
Cholesterol reduction yields clinical benefit. A new look at old data.
A. L. Gould (1995)
10.1161/01.CIR.95.6.1347
New views on the relationship of plasma lipids to cardiovascular disease.
R. Tracy (1997)
10.1161/01.CIR.91.10.2528
Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).
J. Jukema (1995)
10.1161/01.CIR.85.5.1792
Increased Thromboxane Biosynthesis in Type IIa Hypercholesterolemia
G. Daví (1992)
10.1056/NEJM199201233260406
The pathogenesis of coronary artery disease and the acute coronary syndromes (2).
V. Fuster (1992)
10.1097/00019616-199605000-00022
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
TUART (2000)
10.1152/AJPHEART.1993.265.3.H785
Role of sympathetic nerves in the vascular effects of local temperature in human forearm skin.
P. Pergola (1993)
10.1001/JAMA.279.20.1615
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
J. R. Downs (1998)
10.1109/TBME.1980.326582
Evaluation of a Laser Doppler Flowmeter for Measurement of Tissue Blood Flow
G. Nilsson (1980)
10.1161/01.CIR.95.5.1126
Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month.
G. O’Driscoll (1997)
10.1016/S0735-1097(99)00023-6
Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia.
A. Szczeklik (1999)
10.1097/00005344-199801000-00006
Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy.
M. Aviram (1998)
10.1056/NEJM199201303260506
Coronary artery disease: pathogenesis and acute coronary syndromes.
S. Worthley (2001)
10.1161/01.CIR.92.11.3172
Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction.
L. Lacoste (1995)
10.1056/NEJM197402212900805
Platelet function in hyperlipoproteinemia.
A. Carvalho (1974)
10.1056/NEJM199610033351401
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.
F. Sacks (1996)
AM for the AFCAPS/ TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS
JR Downs (1998)
10.1161/01.ATV.13.11.1650
Human type II hyperlipoproteinemia enhances platelet-collagen adhesion in flowing nonanticoagulated blood.
Y. Cadroy (1993)
10.1056/NEJM199705013361802
Coronary risk factors and plaque morphology in men with coronary disease who died suddenly.
A. Burke (1997)
10.1161/01.ATV.11.2.395
Platelet deposition at high shear rates is enhanced by high plasma cholesterol levels. In vivo study in the rabbit model.
J. Badimon (1991)
10.1161/01.CIR.98.3.211
Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study.
S. John (1998)
10.1161/01.ATV.17.2.273
No influence of simvastatin treatment on platelet function in vivo in patients with hypercholesterolemia.
A. Bröijersén (1997)
10.1001/JAMA.280.24.2099
The National Cholesterol Education Program: progress and prospects.
J. Cleeman (1998)
10.1055/S-0037-1615005
Platelet activity in vivo in hyperlipoproteinemia--importance of combined hyperlipidemia.
A. Bröijersén (1998)
10.1016/S0140-6736(96)05190-2
Statins do more than just lower cholesterol
C. Vaughan (1996)
10.1093/EURHEARTJ/16.SUPPL_E.6
Regression or stabilization of atherosclerosis means regression or stabilization of what we don't see in the arteriogram.
V. Fuster (1995)
10.1161/01.CIR.96.12.4424
Cholesterol management in theory and practice.
A. Gotto (1997)
10.1097/00132586-199806000-00060
Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials.
P. Hebert (1997)
10.1161/01.cir.89.3.1333
National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).
S. Grundy (1994)
10.1056/NEJM199811053391902
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
A. Tonkin (1998)



This paper is referenced by
10.1186/1475-2840-5-4
Endothelial dysfunction: a comprehensive appraisal
R. Esper (2006)
Fisiopatología de los síndromes coronarios agudos. Tres paradigmas para un nuevo dogma
J. Vilariño (2004)
10.1016/J.IJCARD.2005.02.011
Effects of early administration of atorvastatin treatment on thrombotic process in normocholesterolemic patients with unstable angina.
D. Tousoulis (2006)
10.1046/j.1365-2362.2003.01179.x
Individuals at increased coronary heart disease risk are characterized by an impaired microvascular function in skin
R. IJzerman (2003)
10.7326/0003-4819-134-3-200102060-00014
Thrombus Formation on Atherosclerotic Plaques: Pathogenesis and Clinical Consequences
U. Rauch (2001)
[Role of coronary risk factors in blood thrombogenicity and acute coronary syndromes].
A. Sambola (2003)
10.1081/CRP-120016435
COST-EFFECTIVENESS ANALYSIS IN THE REAL WORLD: THE CASE OF STATINS
David P. Paul III (2002)
10.15420/AHHJ.2009.7.1.50
Antiplatelet resistance--fact or myth?
P. Gurbel (2009)
Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations : the LIPID trial follow
The Lipid Study Group (2002)
10.3109/09537104.2010.512402
Statins have an early antiplatelet effect in patients with acute myocardial infarction
S. Matetzky (2011)
10.1023/B:THRO.0000036027.39353.70
Evolving Concepts in the Triad of Atherosclerosis, Inflammation and Thrombosis
R. Corti (2004)
10.1253/CIRCJ.66.783
The Mikamo Lecture 2002. Therapeutic targets for the treatment of atherothrombosis in the new millennium--clinical frontiers in atherosclerosis research.
V. Fuster (2002)
10.1093/QJMED/95.10.707
Reducing cholesterol and atherosclerosis: the importance of cellular adhesion molecules?
M. Miller (2002)
10.1016/J.JACC.2006.10.064
Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?
M. Piorkowski (2007)
Design of a thermal diffusion sensor for noninvasive assessment of skin surface perfusion and endothelial dysfunction
V. Li (2008)
10.1016/j.ejvs.2007.12.011
Intensive lipid-lowering therapy ameliorates novel calcification markers and GSM score in patients with carotid stenosis.
N. Kadoglou (2008)
10.1007/s00392-002-0856-5
C-reaktives Protein in koronarem Plaquegewebe
R. Andrié (2002)
10.1136/hrt.2003.027110
Effects of atorvastatin on reactive hyperaemia and the thrombosis–fibrinolysis system in patients with heart failure
D. Tousoulis (2005)
10.1517/13543784.2010.522989
Novel therapeutic strategies targeting vascular endothelium in essential hypertension
Dimitris Tousoulis (2010)
Design and potential clinical impact of a noninvasive thermal diffusion sensor to monitor human peripheral microvascular perfusion in real-time
H. Bowman (2007)
10.1007/978-3-642-32183-2_37
Sibu Olive Inhibits Artherosclerosis by Cholesterol Lowering Effect in Cholesterol Fed-Rabbit
M. Nurulhuda (2013)
10.1016/J.BBRC.2004.04.021
Atorvastatin reduces CD68, FABP4, and HBP expression in oxLDL-treated human macrophages.
G. Llaverías (2004)
Die Bedeutung der Thrombozytenaktivierung in der Pathogenese und Behandlung kardiologischer Erkrankungen
U. Weikert (2007)
10.14740/jocmr1863w
Effect of Statins on Endothelial Function in Patients With Acute Coronary Syndrome: A Prospective Study Using Adhesion Molecules and Flow-Mediated Dilatation
I. Altun (2014)
10.1007/s00109-002-0384-9
Lipoprotein lipase: structure, function, regulation, and role in disease
J. R. Mead (2002)
10.1046/j.1538-7836.2003.00201.x
Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r‐hirudin in a human ex vivo model of arterial thrombosis
T. Sarich (2003)
10.1159/0000115120
Endothelial dysfunction in normal and abnormal glucose metabolism.
R. Esper (2008)
10.1161/01.CIR.0000050621.67499.7D
Role of Risk Factors in the Modulation of Tissue Factor Activity and Blood Thrombogenicity
Antonia Sambola (2003)
10.1016/J.MATURITAS.2005.03.011
Comparison of effects of pravastatin and hormone therapy on soluble P-selectin and platelet P-selectin expression in postmenopausal hypercholesterolemic women.
R. Peverill (2006)
10.1016/S1520-765X(01)90102-6
Atheromatous plaque formation and thrombogenesis: formation, risk factors and therapeutic approaches
L. Badimón (2001)
10.1371/journal.pone.0005263
Atorvastatin Reduces Plasma Levels of Chemokine (CXCL10) in Patients with Crohn's Disease
O. Grip (2009)
10.1016/S0300-8932(03)76998-X
Papel de los factores de riesgo en la trombogenicidad sanguínea y los síndromes coronarios agudos
Antonia Sambola (2003)
See more
Semantic Scholar Logo Some data provided by SemanticScholar